AR104984A1 - Compuestos selectivos para pyy y sus usos - Google Patents

Compuestos selectivos para pyy y sus usos

Info

Publication number
AR104984A1
AR104984A1 ARP160101755A ARP160101755A AR104984A1 AR 104984 A1 AR104984 A1 AR 104984A1 AR P160101755 A ARP160101755 A AR P160101755A AR P160101755 A ARP160101755 A AR P160101755A AR 104984 A1 AR104984 A1 AR 104984A1
Authority
AR
Argentina
Prior art keywords
pyy
compounds
application
selective compounds
refers
Prior art date
Application number
ARP160101755A
Other languages
English (en)
Spanish (es)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR104984A1 publication Critical patent/AR104984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
ARP160101755A 2015-06-12 2016-06-13 Compuestos selectivos para pyy y sus usos AR104984A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15171785 2015-06-12

Publications (1)

Publication Number Publication Date
AR104984A1 true AR104984A1 (es) 2017-08-30

Family

ID=53404384

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101755A AR104984A1 (es) 2015-06-12 2016-06-13 Compuestos selectivos para pyy y sus usos

Country Status (19)

Country Link
US (1) US10005824B2 (OSRAM)
EP (1) EP3307768B1 (OSRAM)
JP (1) JP6731958B2 (OSRAM)
KR (1) KR102476550B1 (OSRAM)
CN (1) CN107849110B (OSRAM)
AR (1) AR104984A1 (OSRAM)
AU (1) AU2016275735B2 (OSRAM)
BR (1) BR112017025108A2 (OSRAM)
CA (1) CA2988500A1 (OSRAM)
ES (1) ES3019234T3 (OSRAM)
IL (1) IL255781B (OSRAM)
MA (1) MA43205A (OSRAM)
MX (1) MX392572B (OSRAM)
MY (1) MY187047A (OSRAM)
RU (1) RU2726777C2 (OSRAM)
SA (1) SA517390445B1 (OSRAM)
TW (1) TWI694082B (OSRAM)
WO (1) WO2016198682A1 (OSRAM)
ZA (1) ZA201707782B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180425T1 (hr) 2010-12-16 2018-04-20 Novo Nordisk A/S Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
SMT201800491T1 (it) 2012-03-22 2018-11-09 Novo Nordisk As Composizioni di peptidi glp-1 e relativa preparazione
ES2688462T3 (es) 2013-05-02 2018-11-02 Novo Nordisk A/S Dosificación oral de compuestos de GLP-1
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
JP6602760B2 (ja) * 2013-11-15 2019-11-06 ノヴォ ノルディスク アー／エス 選択的なｐｙｙ化合物及びその使用
US11229229B2 (en) 2016-06-14 2022-01-25 Purecircle Usa Inc. Steviol glycosides compositions, production methods and uses
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
JP2022543826A (ja) * 2019-08-07 2022-10-14 ノヴォ ノルディスク アー／エス Ｐｙｙ化合物とｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
PH12022551101A1 (en) 2019-11-11 2023-11-13 Boehringer Ingelheim Int Npy2 receptor agonists
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2022029231A1 (en) * 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
CN116745310A (zh) * 2020-11-09 2023-09-12 艾巴克生物科技有限公司 化合物及其在治疗速激肽受体介导的病症中的用途
IL304214B2 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc Compositions and methods for treating metabolic and liver disorders
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
JP2025526148A (ja) 2022-08-18 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157766A1 (en) * 1993-03-29 1994-10-13 Ambikaipakan Balasubramaniam Analogs of peptide yy and uses thereof
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
EP1015007A1 (en) 1996-11-13 2000-07-05 The University Of Cincinnati Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
PE20000564A1 (es) 1998-06-08 2000-07-05 Schering Corp Antagonistas receptores y5 de neuropeptidos
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
MXPA03005388A (es) * 2000-12-14 2003-09-25 Amylin Pharmaceuticals Inc Peptido yy y agonistas de peptido yy para el tratamiento de desordenes metabolicos.
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7811989B2 (en) 2003-01-17 2010-10-12 Ipsen Pharma S.A.S. Peptide YY analogs
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
WO2005028516A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN101380476A (zh) 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
EP2272524A3 (en) 2004-03-17 2011-02-02 7TM Pharma A/S Y2 selective receptor agonists for therapeutic interventions
EA011861B1 (ru) * 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецепторов y2/y4 для терапевтического воздействия
BRPI0508935A (pt) 2004-03-17 2007-09-25 7Tm Pharmas As agonistas de receptor seletivo y4 para intervenções terapêuticas
CN100425282C (zh) 2004-03-17 2008-10-15 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
US7964219B2 (en) * 2004-08-12 2011-06-21 Qps, Llc Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090054326A1 (en) 2005-07-11 2009-02-26 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
RU2008100218A (ru) 2005-07-18 2009-08-27 Ново Нордикс А/С (Dk) Пептиды для лечения ожирения
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
CN101268099A (zh) 2005-09-21 2008-09-17 7Tm制药联合股份有限公司 用于治疗性干预的y4选择性受体激动剂
EP1934245B1 (en) 2005-09-21 2011-07-13 7TM Pharma A/S Y2 selective receptor agonists for therapeutic interventions
KR101059602B1 (ko) 2005-12-07 2011-08-25 에프. 호프만-라 로슈 아게 신경펩타이드 2 수용체 작용물질
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CN101511380B (zh) * 2006-07-11 2012-12-12 昌达生物科技公司 用于持续释放递送肽的药物组合物
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
RU2506273C2 (ru) 2007-07-09 2014-02-10 Импиэриэл Инноувейшнс Лимитид Аналог панкреатического полипептида человека (варианты), фармацевтическая композиция на его основе, способ лечения ожирения или диабета, способ снижения аппетита, уменьшения поглощения пищи или снижения потребления калорий и способ косметического снижения массы посредством указанного аналога
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2187924A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
JP2011520847A (ja) * 2008-05-16 2011-07-21 ノボ・ノルデイスク・エー／エス 遅効型ｙ２及び／又はｙ４レセプターアゴニスト
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
WO2010052144A2 (en) 2008-11-05 2010-05-14 F. Hoffmann-La Roche Ag Neuropeptide-2-receptor (y-2r) agonists and uses thereof
MX2011008774A (es) 2009-02-20 2011-10-24 Ipsen Pharma Sas Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y.
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011045232A2 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
EP2498800A1 (en) 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011131646A1 (en) 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
RU2015144632A (ru) 2013-05-02 2017-06-07 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
JP6602760B2 (ja) * 2013-11-15 2019-11-06 ノヴォ ノルディスク アー／エス 選択的なｐｙｙ化合物及びその使用
US10583172B2 (en) * 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35

Also Published As

Publication number Publication date
MX2017015105A (es) 2018-05-07
RU2726777C2 (ru) 2020-07-15
EP3307768A1 (en) 2018-04-18
ZA201707782B (en) 2019-08-28
CA2988500A1 (en) 2016-12-15
TW201710284A (zh) 2017-03-16
EP3307768C0 (en) 2025-01-29
SA517390445B1 (ar) 2020-12-21
US10005824B2 (en) 2018-06-26
IL255781B (en) 2021-10-31
RU2017145348A (ru) 2019-07-12
EP3307768B1 (en) 2025-01-29
JP6731958B2 (ja) 2020-07-29
MA43205A (fr) 2018-09-19
BR112017025108A2 (pt) 2018-07-31
AU2016275735A1 (en) 2017-12-07
KR102476550B1 (ko) 2022-12-13
CN107849110A (zh) 2018-03-27
JP2018522843A (ja) 2018-08-16
RU2017145348A3 (OSRAM) 2019-09-09
TWI694082B (zh) 2020-05-21
US20170313750A1 (en) 2017-11-02
IL255781A (en) 2018-04-30
MY187047A (en) 2021-08-27
CN107849110B (zh) 2021-11-26
KR20180019616A (ko) 2018-02-26
ES3019234T3 (en) 2025-05-20
AU2016275735B2 (en) 2020-02-06
MX392572B (es) 2025-03-24
WO2016198682A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
UY36124A (es) Derivados de carboxamida
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure